The Filing Desk

agilon health

AGL · NYSE · Health Care · Financials, fiscal 2019 to 2025

AGL · Last close · November 13, 2026
$115.66
Value agilon health yourself

agilon health's revenue fell 2.1% to $5.9 billion in fiscal 2025. Its operating margin was −7.8%, down from −4.8% a year earlier. Free cash flow was −$119 million. The diluted share count rose 0.7%.

agilon health, inc. Latest fiscal year ended December 31, 2025 10-K filed February 25, 2026 · 0001628280-26-011655 Updated
Revenue
$5.9B
2.1%
Operating margin
−7.8%
3.0 pts
Net income
−$391M
 
Free cash flow
−$119M
 
Return on equity
−130.9%
85.0 pts
Market cap
$2.0B
Nov 13 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What agilon health does

agilon health works with independent primary care physician groups that treat older Americans, mostly those in Medicare Advantage, the private plans that run Medicare. It gives these groups technology, staff, processes and capital, so they can take responsibility for their patients' total healthcare costs and quality of care. As of December 31, 2025, it had 28 partner physician groups in 30 geographies across the United States.

agilon sets up a local company in each area. That company signs contracts with health plans, which pay a set monthly fee for each member. The company is then responsible for the members' medical costs. The company also signs long-term agreements, typically lasting 20 years, with its partner physician groups. The groups receive a base payment for their services and share in savings when care improves and costs fall. If medical costs run above the fees, agilon bears the loss.

The physicians on its platform serve about 511,000 Medicare Advantage members. agilon also takes part in federal Medicare programs for people on traditional Medicare, through nine accountable care organizations, which are groups of providers that share responsibility for the cost and quality of care. It says it competes with other organizations that offer similar support to physician groups.

Its biggest risks, as it describes them

  • Failing to find and add new geographies, physician groups and health plans, or to carry out its growth plans.
  • Medical costs for its members that run higher than the fees it receives to pay for their care.
  • Depending on a small number of health plans, whose contracts run for limited terms and may not be renewed.
  • A history of net losses and a need for more money that may not be available on acceptable terms.
  • Changes to Medicare payment rules and models, or audits and investigations by the government or health plans.
From agilon health's annual report on Form 10-K, filed February 25, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

agilon health lost money in fiscal 2025: a net loss of $391 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red. Where the filings' structured data doesn't give a year's earnings per share, the column is blank.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments1,040877488400285
Debt incl. finance leases4944393535
Net debt (negative means net cash)−991−833−450−365−250
Net debt to EBITDA—————
Debt to equity0.0x0.0x0.1x0.1x0.3x
Interest coverage−60.6x−23.5x−34.9x−47.3x−69.8x
Current ratio3.8x2.7x1.5x1.3x1.0x
Quick ratio3.8x2.7x1.5x1.3x1.0x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project agilon health's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

What agilon health says to expect

  • Fiscal year 2026: ACO model adjusted EBITDA contributionAdjusted EBITDA contribution from ACO model entities is expected to be approximately $40-$45 million for fiscal year 2026.
The company's own words, from its earnings release (Form 8-K, Exhibit 99), filed November 4, 2026. They are its expectations, not ours, and not a forecast or price target from The Filing Desk. Replaced when the next release is out.

Insider trades

No officer, director or 10% owner of agilon health reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.

From Form 4 filings with the SEC. Grants, option exercises and shares withheld for tax aren't counted. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score3 of 84 of 81 of 8
Rule of 4076.8%39.2%−4.1%
Altman Z''−0.84−2.57−7.30
Accruals ratio−6.2%−11.7%−19.0%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailFailFail
Return on assets roseFailPassFail
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assetsPassPassFail
Current ratio roseFailFailFail
Share count didn't riseFailFailFail
Gross margin rose———
Revenue rose relative to assetsPassPassFail
F-score3 of 84 of 81 of 8
Companies that report no gross profit are scored on the other eight.

Compare

Put agilon health side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
agilon healthFY25−2.1%−7.8%−2.0%——1
Alignment HealthcareFY2546.1%0.4%2.9%—−6.2x5Compare
Quest DiagnosticsFY2511.8%14.1%12.3%9.5%2.5x6Compare
Amn Healthcare ServicesFY25−8.5%−2.0%8.6%−2.8%7.2x5Compare
BrightSpring Health ServicesFY2528.2%2.3%3.1%5.2%5.3x7Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

7 years of figures

Fiscal yearFY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue7941,2181,5222,3884,3166,0605,933
Revenue growth—53.4%24.9%57.0%80.7%40.4%−2.1%
Gross profit———————
Research and development———————
Operating income−107−57−372−105−232−292−463
Net income−283−60−406−107−263−260−391
Diluted EPS (US$)—−0.20−1.03−0.22−0.48−0.61−0.98
Diluted shares (millions)295324373408409411414
Cash flow
Cash from operations−104−53−148−131−156−58−106
Capital expenditure32715161313
Free cash flow−107−55−155−146−172−71−119
Dividends paid0000000
Share buybacks070020000
Acquisitions00004500
Stock-based compensation5729228705149
Balance sheet at fiscal year end
Cash and short-term investments1391071,040877488400285
Debt incl. finance leases—684944393535
Total assets—4461,5861,6981,7411,7341,271
Total liabilities—4224956571,0801,2631,145
Shareholders' equity−232−2851,0921,041662471127
Margins and ratios
Gross margin———————
Operating margin−13.4%−4.7%−24.5%−4.4%−5.4%−4.8%−7.8%
Net margin−35.6%−4.9%−26.7%−4.5%−6.1%−4.3%−6.6%
Free cash flow margin−13.4%−4.5%−10.2%−6.1%−4.0%−1.2%−2.0%
Rule of 40 (growth + FCF margin)—48.9%14.7%50.8%76.8%39.2%−4.1%
Return on capital————−87.7%——
Return on equity——−100.7%−10.0%−30.8%−45.9%−130.9%
Return on assets——−40.0%−6.5%−15.3%−15.0%−26.0%
Net debt to EBITDA———————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: agilon health's Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with agilon health.